今日新闻！不惧欧盟“下手”！比亚迪创年内新高！

不惧欧盟“下手”！比亚迪创年内新高！

北京，2024年6月14日 - 6月13日，比亚迪（SZ002599）股价强势上涨6%，收于282.8元/股，创下年内新高。比亚迪股价上涨的背后，是其强劲的业绩表现和光明的市场前景。

业绩亮眼，展现强大发展势头

近日，比亚迪发布了2023年年报。报告期内，公司实现营业收入6023.15亿元，同比增长42.04%；实现归母净利润300.41亿元，同比增长80.72%。其中，汽车业务实现营业收入5080.59亿元，同比增长62.78%；电池业务实现营业收入760.71亿元，同比增长23.56%。

比亚迪的亮眼业绩，得益于其在新能源汽车和电池领域的领先优势。在新能源汽车领域，比亚迪已成为全球最大的新能源汽车制造商，产品涵盖乘用车、商用车和专用车等。在电池领域，比亚迪的刀片电池技术拥有领先优势，并已广泛应用于其新能源汽车和储能产品中。

欧盟政策利好，海外市场前景广阔

近期，欧盟发布了一系列利好新能源汽车发展的政策措施，这将进一步推动欧洲新能源汽车市场快速增长。比亚迪作为全球领先的新能源汽车制造商，将充分受益于这一政策红利。

目前，比亚迪已在欧洲多个国家建立了业务，并取得了良好的市场表现。未来，比亚迪将继续加大海外市场拓展力度，进一步提升全球市场份额。

机构看好，未来股价有望继续上行

多家机构对比亚迪的未来发展前景表示看好，并预测其股价有望继续上行。

中信证券表示，比亚迪在新能源汽车和电池领域拥有领先优势，未来发展潜力巨大，预计公司2024年归母净利润将达到500亿元，同比增长66.5%。

国泰君安表示，比亚迪是全球新能源汽车行业的龙头企业，在新能源汽车和电池领域拥有核心技术，未来有望继续保持快速增长。

总体而言，比亚迪的基本面和市场前景都十分看好，股价有望继续创出新高。

以下是一些关于比亚迪的额外信息：

• 比亚迪将于2024年下半年推出全新高端汽车品牌。
• 比亚迪正积极布局海外市场，计划在未来三年内将海外市场销量提升至100万辆。
• 有分析人士认为，比亚迪未来有望成为全球市值最高的汽车公司。

请注意：

• 本文仅供参考，不构成任何投资建议。
• 本文中的信息可能存在误差或遗漏，恕不承担任何责任。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.